What is the Purpose of this Study?
The purpose of this study is to determine how well an experimental drug called KPL-387 works for people who are currently taking medications for the treatment of recurrent pericarditis (RP) and whose pericarditis symptoms are currently under control. Pericarditis is inflammation of the pericardium (2 thin layers of a sac-like tissue that surrounds the heart). A common symptom of pericarditis is chest pain, caused by the sac’s layers becoming inflamed or swollen and possibly rubbing against each other. Researchers aim to learn how to safely and effectively transition participants from their current RP treatments to KPL-387. The study also offers an optional long term extension for those patients that opt in to receiving KPL-387 for an additional period of time. KPL-387 is a monoclonal antibody (protein made in a laboratory), which are often used as drugs to block specific activities of human cells that contribute to disease. KPL-387 is designed to block a specific receptor (called IL-1) that has been shown to contribute to the inflammation of the pericardium. This study will test whether blocking IL-1 with KPL-387 can maintain control of RP, and reduce signs of inflammation, as well as the pain that it causes. KPL-387 is a once-monthly injection.
Eligibility
Not Available
Where can I participate?
Beverly
What is the full name of this clinical trial?
A Phase 2 Posology Study with Long-Term Extension in Participants with Well-Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies